Why the study?
Genetic variants can be used to explore the efficacy and side effects of antihypertensive medications.
Do genetic variants related to nondihydropyridine CCBs inform on the risk of diverticulosis?
Do genetic variants related to nondihydropyridine CCBs inform on the risk of diverticulosis?
Genetic variants related to nondihydropyridine CCBs suggest a potential effect on diverticulosis risk, warranting further investigation.
Answers are grounded in this paper and cite their sources.
Genetic proxies for nondihydropyridine CCBs suggest higher diverticulosis risk; leaves open causality and needs prospective trials.
Genetic variants can be used to explore the efficacy and side effects of antihypertensive medications. The identified potential effect of nondihydropyridine CCBs on diverticulosis risk could have clinical implications and warrants further investigation.
No takes yet. Share an insight, caveat, or question.
Gill et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: